Skip to content

Clinical trials

Observational Hyperlipidemias trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hyperlipidemias Phase: Observational Clear all

103 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20021
20031
20043
20055
20063
20078
20083
200910
20102
20112
20123
20134
20144
20156
20161
20173
20182
20191
20205
20211
20228
20237
20249
20251
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed56
Unknown status19
Recruiting10
Withdrawn5
Not yet recruiting5
Terminated4
Enrolling by invitation2
Active, not recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca9
Ohio State University3
Peking University Third Hospital3
Chinese University of Hong Kong2
Elpen Pharmaceutical Co. Inc.2
National Heart, Lung, and Blood Institute (NHLBI)2
National Taiwan University Hospital2
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.2
Riphah International University2
Takeda2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hyperlipidemias103
Hypertension30
Diabetes Mellitus27
Cardiovascular Diseases15
Atherosclerosis13
Obesity13
Dyslipidemias11
Hypercholesterolemia11
Metabolic Syndrome11
Coronary Artery Disease8

Trials

Showing 26 to 50 of 103. Each trial links to its page on Pharma Observatory.

3 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.